Trifecta Capital Advisors LLC Has $6.83 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX

Trifecta Capital Advisors LLC boosted its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 5.5% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,340 shares of the pharmaceutical company’s stock after purchasing an additional 802 shares during the period. Trifecta Capital Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $6,829,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of VRTX. Activest Wealth Management acquired a new stake in Vertex Pharmaceuticals during the 1st quarter worth about $25,000. Clal Insurance Enterprises Holdings Ltd grew its holdings in Vertex Pharmaceuticals by 450.0% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 45 shares during the period. Flaharty Asset Management LLC acquired a new stake in Vertex Pharmaceuticals during the 1st quarter worth about $32,000. American National Bank & Trust grew its holdings in Vertex Pharmaceuticals by 515.4% during the 2nd quarter. American National Bank & Trust now owns 80 shares of the pharmaceutical company’s stock worth $36,000 after acquiring an additional 67 shares during the period. Finally, University of Texas Texas AM Investment Management Co. acquired a new stake in Vertex Pharmaceuticals during the 1st quarter worth about $46,000. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs purchased 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 6th. The shares were acquired at an average price of $389.68 per share, with a total value of $1,948,400.00. Following the transaction, the director owned 45,000 shares in the company, valued at $17,535,600. The trade was a 12.50% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on VRTX shares. Leerink Partners upgraded Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and decreased their price target for the stock from $458.00 to $456.00 in a report on Thursday, September 25th. UBS Group set a $553.00 price target on Vertex Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, August 5th. Stifel Nicolaus cut their price objective on shares of Vertex Pharmaceuticals from $494.00 to $455.00 and set a “hold” rating on the stock in a research report on Tuesday, August 5th. Raymond James Financial began coverage on shares of Vertex Pharmaceuticals in a research report on Tuesday, September 2nd. They set a “market perform” rating on the stock. Finally, Royal Bank Of Canada cut their price objective on shares of Vertex Pharmaceuticals from $430.00 to $405.00 and set a “sector perform” rating on the stock in a research report on Tuesday, August 5th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and twelve have given a Hold rating to the company. According to data from MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $494.43.

Vertex Pharmaceuticals Stock Performance

Shares of NASDAQ VRTX opened at $421.15 on Thursday. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $362.50 and a fifty-two week high of $519.88. The stock has a market cap of $107.98 billion, a price-to-earnings ratio of 30.10 and a beta of 0.43. The firm’s 50-day simple moving average is $395.83 and its 200 day simple moving average is $440.97.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share for the quarter, beating the consensus estimate of $4.24 by $0.28. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The business had revenue of $2.94 billion for the quarter, compared to analysts’ expectations of $2.90 billion. During the same quarter last year, the firm earned ($12.83) EPS. The firm’s revenue for the quarter was up 11.3% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.